Therapeutics: Delving deeper into resistance

Nature Reviews Cancer

Volumn 14, Issue 1, 2014, Pages 7-

  Seton Rogers, Sarah ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; B RAF KINASE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; G PROTEIN COUPLED RECEPTOR; HISTONE DEACETYLASE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN KINASE B INHIBITOR;

EXOME; GAIN OF FUNCTION MUTATION; HUMAN; MELANOMA; NOTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION;

EID: 84890949712     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3653     Document Type: Note

References (5)

1. Johannessen, C. M. et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 504, 138-142 (2013)
2. Shi, H. et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. http://dx. doi.org/10.1158/2159- 8290.CD-13-0642 (2013)
3. Shi, H. et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. http://dx.doi.org/10.1158/2159- 8290.CD-13-0279 (2013)
4. Van Allen, E. M. et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. http://dx.doi.org/10.1158/ 2159-8290.CD-13-0617 (2013)
5. Wagle, N. et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. http://dx.doi. org/10.1158/2159-8290.CD-13-0631 (2013)